Lilly weight loss drug results

Eli Lilly's next-generation weight loss injection, retatrutide, has delivered record-breaking results in a late-stage clinical trial.

Participants lost an average of 28% of their body weight over 80 weeks, outpacing existing drugs on the market.

The results from the Phase 3 trial show that nearly half of the participants lost more than 30% of their total weight, a milestone previously unseen in non-surgical interventions.

Lilly plans to seek regulatory approval for the drug later this year, with a potential market launch in 2027.

Medical experts suggest the drug could revolutionize the treatment of obesity-related conditions and improve long-term health outcomes for millions of patients.